Tirzepatide vs Semaglutide: Which One Causes More Weight Loss in 2026?

If weight loss is the only question, tirzepatide currently has the edge. In the strongest direct comparison so far, people taking tirzepatide lost an average of 20.2% of their starting weight over 72 weeks, compared with 13.7% with semaglutide. A 2026 meta-analysis combining 12 comparative studies reached the same overall conclusion: tirzepatide produced greater average weight loss.

That does not mean semaglutide suddenly became a weak medication. Losing around 14% of body weight is substantial. The interesting part is that when the two drugs finally went head-to-head at obesity-treatment doses, tirzepatide did not just win by a fraction — the average difference was large enough to matter.

Related: tirzepatide vs retatrutide, the tirzepatide dosage guide and before and after results.

Brand names explained: Mounjaro vs Zepbound. Prefer a pill? See is there a tirzepatide pill.

For years, people compared tirzepatide and semaglutide using separate trials. That was useful, but never quite satisfying.

Different trials recruit different people, use different protocols, and happen at different times. Comparing a number from one study with a number from another can make two drugs look more directly comparable than they really are.

SURMOUNT-5 finally put the two medications into the same trial.

The study randomized 751 adults with obesity or overweight and at least one weight-related condition, but without type 2 diabetes. Participants received the maximum tolerated dose of either tirzepatide or semaglutide for 72 weeks.

At 72 weeks, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide.

That is a difference of 6.5 percentage points of starting body weight.

Percentages can sound abstract, so imagine two people who both start at 250 pounds. A 20.2% reduction is about 50.5 pounds. A 13.7% reduction is about 34.3 pounds. That is roughly a 16-pound gap between the treatment averages.

The actual trial averages were almost exactly that: about 50 pounds lost with tirzepatide versus about 33 pounds with semaglutide.

These are illustrations based on trial averages, not predictions for an individual person. Some participants lost far more, some far less, and some stopped treatment before the study ended.

Averages can hide what is happening across the group, so researchers also looked at how many people crossed major weight-loss milestones.

Tirzepatide beat semaglutide at every major threshold measured in SURMOUNT-5: at least 10%, 15%, 20%, and 25% weight loss. In other words, the result was not being driven only by a handful of spectacular responders.

Waist circumference told the same story. Average reduction was 18.4 cm with tirzepatide versus 13.0 cm with semaglutide.

One head-to-head trial is powerful evidence. The next question is whether the same pattern survives when researchers combine the broader comparison literature.

A systematic review and meta-analysis published in 2026 included 12 randomized and observational studies that directly compared tirzepatide with semaglutide.

Across those studies, tirzepatide was associated with about 4.61 percentage points more body-weight reduction and about 4.76 kg more absolute weight loss than semaglutide on average.

People taking tirzepatide were also more likely to reach 5%, 10%, 15%, and 20% weight-loss milestones.

The studies were highly heterogeneous.

That is researcher language for "these studies were not all telling exactly the same story under exactly the same conditions." They differed in populations, doses, follow-up, study design, and other details. Several were observational rather than randomized trials.

So the meta-analysis strengthens the overall pattern, but the cleanest single comparison remains the randomized SURMOUNT-5 trial.

A separate 2026 BMJ network meta-analysis examined 262 randomized trials involving nearly 100,000 participants across multiple weight-loss medications.

At one year, tirzepatide was estimated to reduce body weight by about 14.9 percentage points more than lifestyle modification alone. Subcutaneous semaglutide was estimated at about 9.8 percentage points.

That analysis was not a simple direct tirzepatide-versus-semaglutide trial, so it should not replace SURMOUNT-5. But it independently lands in the same place: tirzepatide sits among the strongest currently available weight-loss medications.

The obvious biological difference is that semaglutide mainly targets the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors.

Both drugs can reduce appetite, affect fullness, slow digestion, and improve metabolic control. Tirzepatide adds a second incretin pathway, and the combined effect appears to produce greater average weight reduction.

That explanation is biologically appealing, but it is important not to oversimplify it into "two hormones are automatically twice as good as one." Human physiology is not that tidy, and the actual trial difference is much smaller than twofold.

Not automatically.

If your only scoreboard is percentage of body weight lost, the current evidence favors tirzepatide. Real treatment decisions have more columns than that.

A medication that produces a higher average in a study is not necessarily the better medication for every individual person.

This is one of the easiest ways to make the comparison confusing.

Semaglutide is an ingredient, not a single dose or brand. Wegovy is the semaglutide product used for chronic weight management. Ozempic also contains semaglutide but is used in the diabetes setting and has a different dosing context.

SURMOUNT-5 compared tirzepatide with obesity-dose semaglutide — effectively the Zepbound-versus-Wegovy question — not tirzepatide against a random lower dose of semaglutide.

Both medications are famous for the same general family of complaints: nausea, diarrhea, constipation, vomiting, uncomfortable fullness, and other gastrointestinal problems.

In SURMOUNT-5, gastrointestinal adverse events were the most common side effects in both groups. Most were mild to moderate and occurred mainly while doses were being increased.

The comparison is not as simple as "the stronger drug causes more side effects." Tolerability varies enormously between individuals, which is why somebody can struggle on semaglutide and do well on tirzepatide — or the reverse.

The existence of a medication with a higher average does not erase a good result.

If semaglutide is working, tolerable, accessible, and producing a meaningful result, a population average does not automatically create a reason to switch.

This is where comparison articles can become misleading. They make medications look like phones: model A has the bigger number, so throw away model B. Treatment does not work that way.

This is where the comparison becomes more personally interesting.

Someone who has reached a long plateau, cannot reach a clinically useful result, or is discussing alternatives with their clinician may reasonably want to know that tirzepatide has produced greater average weight loss in direct research.

But switching medication is not something to improvise from a comparison chart. Dose transitions, side effects, contraindications, glucose-lowering medications, and other medical factors matter.

A 20.2% average does not mean every tirzepatide user loses 20%. A 13.7% average does not put a ceiling on semaglutide.

There were strong responders and weaker responders in both groups. A person taking semaglutide can lose more weight than another person taking tirzepatide.

The correct interpretation is about probabilities and averages: if you take comparable groups of people and treat them under similar conditions, the tirzepatide group is currently expected to lose more weight.

Tirzepatide.

That answer is now supported by a direct randomized head-to-head trial, multiple comparative studies, a 2026 direct-comparison meta-analysis, and a large 2026 network meta-analysis.

The strongest head-to-head number remains easy to remember: about 20% average weight loss with tirzepatide versus about 14% with semaglutide over 72 weeks in adults with obesity without diabetes.

If you are already taking semaglutide and are thinking about a change, our guide to switching from semaglutide to tirzepatide explains how doctors usually plan the transition.

Liraglutide is the older GLP-1 option many people compare as well. Our guide to liraglutide vs tirzepatide covers daily vs weekly dosing, trial results and the Saxenda changes.

Semaglutide changed obesity treatment. Tirzepatide appears to push average weight loss further.

In the cleanest direct trial, the difference was 20.2% versus 13.7%. In the 2026 meta-analysis, tirzepatide again came out ahead. That makes tirzepatide the stronger weight-loss option on average based on the evidence available today.

But "which drug loses more weight?" and "which drug should I take?" are two different questions. Research can answer the first one surprisingly well. The second one still depends on the person.

This comparison is based on direct head-to-head research and systematic evidence reviews:

Study averages describe groups rather than predicting an individual result. Dose, treatment duration, diabetes status, other medications, side effects, adherence, access, and individual biology can all affect weight loss. Written for general education; this page is not medical advice. Tirzepatide.review is independent and is not affiliated with, sponsored by, or endorsed by Eli Lilly, Novo Nordisk, or their products.